DNAワクチンの世界市場見通し

◆英語タイトル:Global DNA Vaccine Market Outlook 2022
◆商品コード:RNCS60902
◆発行会社(調査会社):RNCOS
◆発行日:2016年8月
◆ページ数:85
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD1,800 ⇒換算¥205,200見積依頼/購入/質問フォーム
Multi UserUSD2,500 ⇒換算¥285,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はRNCOS社の日本における正規販売代理店です。RNCOS社の概要及び新刊レポートはこちらでご確認いただけます。
※本調査レポートでは、DNAワクチンの世界市場について調査・分析し、市場概要、市場動向、市場展望、DNAワクチンの世界市場規模、地域別市場規模、セグメント別市場規模、主要企業分析などの情報をお届けいたします。

1. アナリストの見解
2. 調査方法
3. DNAワクチン概要
4. 成長要因および課題
5. DNAワクチン市場概要
6. 地域別DNAワクチン市場
7. 種類別DNAワクチン市場
8. 需要先別DNAワクチン市場
9. 治療適用別DNAワクチン市場
10. パイプライン分析
11. 動向
12. 企業概要
13. 提言
【レポートの概要】

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines. Various vaccines have been introduced in the market based on this technique. Some of the major DNA vaccines include GlaxoSmithKline’s Engerix-B, Twinrix, and Fendrix; Merck’s Gardasil, and Recombivax HB; Protein Sciences Corporation’s Flublok, etc. Currently, the researchers are engaged in developing genetic vaccines for humans. Animal genetic vaccines are already present in the market. These vaccines are third generation vaccines, and contain DNA that codes for specific proteins from a pathogen. This DNA is injected into host body and produces protein for which the body generates immune response.
This comprehensive report by RNCOS entitled “Global DNA Vaccine Market Outlook 2022” provides an in-depth analysis of the global DNA Vaccines market, presenting readers a profound understanding of the various challenges, drivers, and developments in this industry. The study has publicized that though the numbers of DNA vaccines that target the human clinical segment are relatively fewer in number, however due to high sales of these vaccines, the DNA vaccine market is estimated to reach US$ 7 Billion by the end of 2016.

The report also contains detailed and in-depth analysis of the segmentation of the DNA vaccines market based on types of DNA vaccines, therapeutic indication, end-users, and geography. Based on the type, the DNA vaccines market is divided into recombinant protein and genetic. In 2016, recombinant protein segment is estimated to account for largest share in the market. This large share is attributed to the presence of high number of recombinant protein vaccines in the market.

Based on end-user, the report segments the market into human and animal. The majority of DNA vaccines available in the market are targeted for humans. Moreover, the strong pipeline of human targeted vaccines is likely to aid the market growth.

Based on geography, the report further divides the market into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World. North America is the largest market for DNA vaccines. The large share of the market is attributed to government’s initiatives to immunize citizens, coupled with high awareness regarding the benefits of genetic vaccines targeted towards animals. The Asia-Pacific region is slated to witness the highest growth in the forecasted period. This growth is likely to be driven by rising awareness of people regarding the advantages of immunization against HPV and Hepatitis B.

The report also includes pipeline analysis based on the type of phase, therapeutic indications, and type of diseases for which the vaccines have been designed, such as infectious and vector borne diseases, and various types of cancers.

Major players in the DNA Vaccines market are also profiled with company overview, financial overview, product portfolios, recent developments, and strengths and weaknesses. The last section of the report discusses about the recommendations which could help the DNA vaccine market grow at a faster pace. Conclusively, the research will prove to be a useful resource for all debut makers in DNA vaccine industry, and potential investors.

【レポートの目次】

1. Analyst View
2. Research Methodology
3. DNA Vaccine – An Introduction
4. Drivers & Challenges
4.1 Drivers
4.1.1 Increasing Investment
4.1.2 Advantages of DNA Vaccines over Traditional Vaccines
4.1.3 Dramatic Increase in Chronic Disorders
4.1.4 Strong DNA Vaccine Pipeline
4.1.5 Technological Advancements
4.2 Challenges
4.2.1 Uncertainty in Regulatory System
4.2.2 Lack of Awareness in Developing Countries
4.2.3 Development Limited to Plasmid Vectors
5. DNA Vaccine Market Overview
6. DNA Vaccines Market by Geography
6.1 North America
6.2 Europe
6.3 Asia Pacific
7. DNA Vaccine Market by Type
7.1 Recombinant Protein Vaccines
7.1.1 By Geography (North America, Europe, Asia Pacific)
7.2 Genetic Vaccines
7.2.1 By Geography (North America, Europe, Asia-Pacific)
8. DNA Vaccines Market by End User
8.1 Human
8.2 Animal
9. DNA Vaccines Market by Therapeutic Indication
9.1 Infectious & Vector Borne Diseases
9.2 Cancer
10. Pipeline Analysis
11. Trends
11.1 Increasing Focus on Genetic Vaccine Development
11.2 Expanding Applications Increasing Popularity of DNA Vaccines
11.3 Partnerships Enhancing Genetic Vaccines Development
12. Company Profiles
12.1 Novartis International AG
12.2 Merck & Co., Inc
12.3 GlaxoSmithKline plc.
12.4 Sanofi
12.5 Zoetis
12.6 Green Cross Corporation
12.7 Inovio Pharmaceuticals, Inc.,
12.8 Bharat Biotech
12.9 Protein Sciences Corporation
12.10 Indian Immunologicals Ltd.
12.11 Serum Institute of India Pvt. Ltd
13. Recommendations

List of Figures:

Figure 5-1: Share of DNA Vaccines in Global Vaccine Market (%), 2016
Figure 5-2: Share of DNA Vaccines in Global Vaccine Market (%), 2022
Figure 5-3: Global – DNA Vaccine Market (Billion US$), 2016-2022
Figure 6-1: Global – DNA Vaccine Market by Geography (%), 2016
Figure 6-2: Global – DNA Vaccine Market by Geography (%), 2022
Figure 6-3: North America – DNA Vaccine Market (Billion US$), 2016 & 2022
Figure 6-4: Europe – DNA Vaccine Market (Billion US$), 2016 & 2022
Figure 6-5: Asia Pacific – DNA Vaccine Market (Billion US$), 2016 & 2022
Figure 7-1: Global – DNA Vaccine Market by Type (%), 2016
Figure 7-2: Global – DNA Vaccine Market by Type (%), 2022
Figure 7-3: Global – Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
Figure 7-4: Global – Recombinant Protein Vaccines Market by Geography (%), 2016
Figure 7-5: Global – Recombinant Protein Vaccines Market by Geography (%), 2022
Figure 7-6: North America – Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
Figure 7-7: Europe – Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
Figure 7-8: Asia Pacific – Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
Figure 7-9: Global – Genetic Vaccines Market (Billion US$), 2016 & 2022
Figure 7-10: Global – Genetic Vaccines Market by Geography (%), 2016
Figure 7-11: Global – Genetic Vaccines Market by Geography (%), 2022
Figure 7-12: North America – Genetic Vaccines Market (Billion US$), 2016 & 2022
Figure 7-13: Europe – Genetic Vaccines Market (Billion US$), 2016 & 2022
Figure 7-14: Asia Pacific – Genetic Vaccines Market (Billion US$), 2016 & 2022
Figure 8-1: Global – DNA Vaccine Market by End User (%), 2016
Figure 8-2: Global – DNA Vaccine Market by End User (%), 2022
Figure 8-3: Global – Human DNA Vaccine Market (Billion US$), 2016 & 2022
Figure 8-4: Global – Animal DNA Vaccine Market (Billion US$), 2016 & 2022
Figure 9-1: Global – DNA Vaccine Market by Therapeutic Segment (%), 2016
Figure 9-2: Global – DNA Vaccine Market by Therapeutic Segment (%), 2022
Figure 9-3: Global – DNA Vaccine Market for Infectious & Vector Borne Diseases (Billion US$), 2016 & 2022
Figure 9-4: Global – DNA Vaccine Market for Cancer (Billion US$), 2016 & 2022
Figure 10-1: Global – DNA Vaccine Pipeline Analysis by Phase (%), 2016
Figure 10-2: Global – DNA Vaccine Pipeline by Therapeutic Indication (%), 2016
Figure 10-3: Global – DNA Vaccine Pipeline by Vaccine Type (%), 2016
Figure 10-4: Global – DNA Vaccine Pipeline by Application (%), 2016
Figure 12-1: Novartis – Break-up of Revenue by Product Category (%), 2015
Figure 12-2: Novartis – Break-up of Revenue by Geographical Region (%), 2015
Figure 12-3: Merck & Co. Inc – Break-up of Revenue by Product Category (%), 2015
Figure 12-4: Merck & Co. Inc – Break-up of Revenue by Geographical Region (%), 2015
Figure 12-5: GlaxoSmithKline – Break-up of Revenue by Product Category (%), 2015
Figure 12-6: GlaxoSmithKline – Break-up of Revenue by Geographical Region (%), 2015
Figure 12-7: Sanofi – Break-up of Revenue by Product Category (%), 2015
Figure 12-8: Sanofi – Break-up of Revenue by Geographical Region (%), 2015
Figure 12-9: Zoetis – Break-up of Revenue by Product Category (%), 2015
Figure 12-10: Zoetis – Break-up of Revenue by Geographical Region (%), 2015
Figure 12-11: Green Cross Corporation – Break-up of Revenue by Geographical Region (%), 2015

List of Tables:

Table 10-1: Global – DNA Vaccines Pipeline
Table 12-1: Novartis International AG – Product Portfolio
Table 12-2: Novartis International AG – Pipeline Analysis
Table 12-3: Novartis – Key Financials (Million US$), 2013-2015
Table 12-4: Merck & Co. Inc – Product Portfolio
Table 12-5: Merck & Co. Inc – Key Financials (Million US$), 2013-2015
Table 12-6: GlaxoSmithKline – Product Portfolio
Table 12-7: GlaxoSmithKline – Key Financials (Million US$), 2013-2015
Table 12-8: Sanofi – Product Portfolio
Table 12-9: Sanofi – Pipeline Analysis
Table 12-10: Sanofi – Key Financials (Million US$), 2013-2015
Table 12-11: Zoetis – Product Portfolio
Table 12-12: Zoetis – Key Financials (Million US$), 2013-2015
Table 12-13: Green Cross Corporation – Product Portfolio
Table 12-14: Green Cross Corporation – Key Financials (Million US$), 2013-2015
Table 12-15: Inovio Pharmaceuticals – Key Financials (Million US$), 2013-2015
Table 12-16: Inovio Pharmaceuticals – Pipeline Analysis
Table 12-17: Bharat Biotech – Product Portfolio
Table 12-18: Protein Sciences Corporation – Product Portfolio
Table 12-19: Protein Sciences Corporation – Pipeline Analysis
Table 12-20: Indian Immunologicals Ltd. – Product Portfolio
Table 12-21: Serum Institute of India Pvt. Ltd. – Product Portfolio
Table 12-22: Serum Institute of India Ltd. – Pipeline Analysis



★調査レポート[DNAワクチンの世界市場見通し]販売に関する免責事項
★調査レポート[DNAワクチンの世界市場見通し]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆